Impact Biomedical Inc. income statement

In fiscal 2025, Impact Biomedical Inc. reported revenue of $32,000, down 36.0% on the year before, operating income of −$4.3m (a -13381.3% margin) and net income of −$11.8m, or −$0.38 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Impact Biomedical Inc.: income statement, annual
Fiscal year	2022Dec 2022	2025Dec 2025	LTMJun 2026
Revenue	0	0	0
Cost of revenue	—	0	—
Gross profit	—	−0	—
Research and development	1	0	0
Selling, general and administrative	0	1	2
Operating income	−3	−4	−5
Interest expense	0	1	—
Income before tax	−8	−14	−2
Income tax	−1	−3	—
Net income	−7	−12	1
Diluted EPS	−$0.10	−$0.38	—
Diluted shares (average)	70m	32m	—
EBITDA	−2	−3	−4

US$ millions unless shown otherwise. Fiscal quarters.

Impact Biomedical Inc.: income statement, quarterly
Quarter	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	0	0	0	0	0	0
Cost of revenue	—	—	—	0	0	0	—	0
Gross profit	—	—	—	0	0	−0	—	0
Research and development	0	0	1	0	0	0	0	0
Selling, general and administrative	0	0	0	0	0	0	2	0
Operating income	−1	−1	−1	−1	−1	−1	−2	−1
Interest expense	0	0	0	0	0	0	—	—
Income before tax	−1	−1	−5	−14	−1	3	−2	−1
Income tax	—	1	−2	—	—	—	—	—
Net income	−1	−2	−3	−14	−1	5	−2	−1
Diluted EPS	$0.00	−$0.03	−$0.04	−$1.18	−$0.12	$1.03	−$0.02	−$0.01
EBITDA	−0	−1	−1	−1	−1	−1	−2	−0

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IBO vs LYEL AIM vs IBO IBIO vs IBO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Impact Biomedical Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Impact Biomedical Inc.